药物对比
Tirzepatide vs Pioglitazone
比较Tirzepatide（Mounjaro）与Pioglitazone（Actos）治疗2型糖尿病。双重GIP/GLP-1受体激动剂与TZD：A1C、减重与增重、心血管风险、警告。
此页面暂无可用的对比维度。
临床背景
Type 2 diabetes patients comparing injectable dual incretin agonist tirzepatide against oral TZD pioglitazone for control, weight, and heart risks.
结论
Tirzepatide typically outperforms pioglitazone in A1C and weight loss for T2D but is injectable with GI effects.
全部药物对比